Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development

Annie E Wolfe; Jacob E Moskowitz; Craig L Franklin; Timothy L Wiemken; Aaron C Ericsson

doi:10.1371/journal.pone.0236595

. 2020 Jul 24;15(7):e0236595. doi: 10.1371/journal.pone.0236595

Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development

Annie E Wolfe ^1,^#, Jacob E Moskowitz ^2,^#, Craig L Franklin ^1,^2,^3,^4,^5,^#, Timothy L Wiemken ⁶, Aaron C Ericsson ^1,^2,^3,^4,^5,^*,^#

Editor: Hiroyasu Nakano⁷

PMCID: PMC7380633 PMID: 32706816

Abstract

Colorectal cancer (CRC) risk is influenced by host genetics, sex, and the gut microbiota. Using a genetically susceptible mouse model of CRC induced via inoculation with pathobiont Helicobacter spp. and demonstrating variable tumor incidence, we tested the ability of the Th17-enhancing commensal Candidatus Savagella, more commonly denoted as Segmented Filamentous Bacteria (SFB), to influence the incidence and severity of colitis-associated CRC in male and female mice. To document the composition of the gut microbiota during CRC development and identify taxa associated with disease, fecal samples were collected before and throughout disease development and characterized via 16S rRNA sequencing. While there were no significant SFB-dependent effects on disease incidence or severity, SFB was found to exert a sex-dependent protective effect in male mice. Furthermore, SFB stabilized the GM against Helicobacter-induced changes post-inoculation, resulting in a shift in disease association from Helicobacter spp. to Escherichia coli. These data support sex-dependent SFB-mediated effects on CRC risk, and highlight the complex community dynamics within the GM during exposure to inflammatory pathobionts.

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the United States. In 2017 alone, there were an estimated 50,260 deaths [1]. Colitis-associated CRC (CAC) is a devastating sequela of inflammatory bowel diseases (IBD) such as Ulcerative Colitis (UC) and Crohn’s Disease (CD), recurrent, chronic inflammatory diseases affecting the colon or any region of the gastrointestinal tract (GIT) respectively [2]. The risk of developing CAC increases with the duration of IBD, reaching twenty percent after thirty years duration [3]. Although CAC represents less than two percent of cases of CRC, the challenges posed by difficulty of detection and treatment of this subset negatively affect prognosis [4–6].

Inflammation, among other risk factors of CRC, such as diet, smoking, and obesity, have a complex relationship with the gut microbiota (GM) [1–3]. The gut microbiota is the ecosystem of microorganisms inhabiting the GIT, with a profound influence on immune development and function, nutrient absorption and metabolite generation, and susceptibility to diseases of the gut and peripheral systems [7]. IBD-specific models such as the IL-10 knockout mouse have implicated different naturally occurring GM profiles in modulating severity of disease [8]. Genetically identical IL-10 knockout mice on a C57BL/6J background harboring a GM inherited from Taconic mice exhibit more severe inflammation than those harboring a GM originating from Charles River mice [8]. These data demonstrate that different GM profiles among genetically susceptible individuals can significantly affect the severity of intestinal inflammation which contributes to increased risk of CAC. Delineating the mechanisms behind this relationship could help to identify potential therapies to decrease the risk of CAC development in IBD patients.

Mutations affecting the TGF-β pathway, an anti-inflammatory and pro-apoptotic cytokine, are commonly cited as an inciting incident for CRCs [9]. For this reason, Smad3^-/- mice, harboring a deletion for the Smad3 signaling molecule downstream of the TGF-β receptor, are often used in combination with pathobiont bacterial species such as Helicobacter bilis and H. hepaticus to study colitis-associated CRC [2, 10]. These Helicobacter spp. are suspected to act as provocateurs, instigating a host immune response against other commensal bacteria [11, 12], and thus creating an environment of chronic intestinal inflammation as a driver of CRC development. Smad3^-/- mice which do not receive this trigger do not develop CRC [10].

However, only 20–66% of Helicobacter spp.-inoculated Smad3^-/- mice develop CRC by 14 weeks post-inoculation [2, 10]. Because the GM is known to vary from institution to institution [13], and has already been shown to affect disease phenotype of similar models such as the IL-10^-/- IBD model [8] and the Pirc rat CRC model [14], we hypothesized that initial static features or subsequent dynamic shifts of the GM following Helicobacter spp.-inoculation would modulate disease incidence and severity in the Smad3^-/- CRC model.

We also introduced segmented filamentous bacteria (SFB, Candidatus Savagella) into our Smad3^-/- model due to its status as a keystone species in the modulation of IgA production and Th17 differentiation [15–17], two important components of mucosal inflammatory host responses to the GM. Historically, SFB colonizes most inbred specific pathogen-free (SPF) mice from Charles River Laboratories, Envigo, and many strains from Taconic, but rarely mice from the Jackson Laboratory [16, 17], contributing to variation in disease phenotype in models of IBD [18], Rheumatoid Arthritis [19], type 1 diabetes [20], and multiple sclerosis [21]. Moreover, increased colonization with SFB has been anecdotally associated with ulcerative colitis in people [22], and SFB is believed to enhance induction of Th17 in people as it does in rodents [23].

Thus, using the Smad3^-/- model, we sought to identify individual bacteria, or combinations of bacteria, which may contribute to the observed differential susceptibility to CAC. Building on previous findings, we were particularly interested in the composition of the GM prior to, and shortly after, inoculation with Helicobacter spp., at the same time that host inflammatory markers are predictive of CAC later in life [2]. Our ultimate objective is a better understanding of the role that SFB and the background GM play in colitis-associated cancer development, in order to develop therapeutic strategies that address and reduce risk of CRC development in IBD patients.

Results

Experimental design

An in-house colony of Smad3^-/- mice (a gift from Lillian Maggio-Price and originally from the Jackson Laboratory) was divided into two groups of breeding trios and pairs. One group received an inoculation of pure SFB, obtained from endemically colonized BALB/cAnNHsd as previously described [24], while the other group retained its original GM. Breeders were allowed to give birth, thus transferring their gut microbiota vertically to several generations of pups which were used as cohorts in this study. With the understanding that SFB colonization often wanes to undetectable levels over time [25–27], and that the previously reported CRC-predictive spike in pro-inflammatory host mRNAs such as IL-1β occurs as early as one week post-Helicobacter spp.-inoculation [2], presence of SFB was confirmed through fecal PCR screening at critical early timepoints from four to five weeks of age following Helicobacter spp.-inoculation to assess early events in the development of CAC. Those which tested positive for SFB are referred to as SFB+ and those which did not are SFB-. Pups from SFB+ breeders which tested negative for SFB by PCR were removed from the study.

SFB+ and SFB- weanling Smad3^-/- mice were inoculated by gastric gavage with approximately 1×10⁸ CFU mixture of Helicobacter hepaticus and H. bilis twice, twenty-four hours apart. Freshly evacuated fecal pellets were collected between 6 a.m. and 7 a.m. at the following timepoints: pre-inoculation (pre), before the second inoculation (mid), Day 1 (D1), D4, D7, 2 weeks (2W), 3W, 5W, 8W, and 14W post-inoculation (PI) (Fig 1A). Cecal contents were also collected at necropsy at 14 weeks PI. Following sacrifice, colonic tissue was analyzed histologically and then scored based on epithelial changes, inflammation, and tumor size and invasiveness (Fig 1B and 1C). DNA from each fecal sample was analyzed via 16S rRNA amplicon sequencing for a snapshot of the GM at each time-point for each mouse, and then retroactively categorized based on lesion scores or the presence/absence of CRC at sacrifice.

Fig 1 — A) Two subcolonies of Smad3^-/- mice were maintained concurrently. SFB+ mice were generated by gastric gavage of Smad3^-/- breeders with pure SFB inoculum or sham, and subsequent breeding to generate experimental mice. At weaning (21 days old), mice from the SFB- and SFB+ colonies were inoculated via gastric gavage with two doses of *Helicobacter hepaticus* and *Helicobacter bilis* at approximately 1×10⁸ CFUs per inoculum. Fecal samples were collected prior to inoculation (Pre), between the two inoculations (mid), then Day 1 (D1), D4, D7, 2W (two weeks), 3W, 5W, 8W, and 14W post-inoculation (PI). Mice were euthanized at 14 weeks, cecal contents collected, and colon collected for histopathological examination and lesion scoring. B) Representative Haemotoxylin and Eosin (H&E) stained colons of Smad3^-/- mice sacrificed 14W post-inoculation showing i) severe inflammation of tissue and ii) adenocarcinoma invading into the lamina muscularis, exhibiting branched structure and cell hyperplasia. C) The lesion scoring system for colons in this study, taking into account epithelial changes, inflammation, and tumor scores to generate an overall score. Drawings are property of Annie E. Wolfe, an author of this paper.

A spike in pro-inflammatory host mRNAs such as IL-1β as early as D7 PI is predictive of CRC development in Smad3^-/- mice [2]. For this reason, and in order to assess key changes in the GM before tumor development can contribute to changes in the GM, we focused primarily on the early time-points in this study.

No SFB-dependent difference in penetrance or severity of CAC

Overall, regardless of SFB status, Helicobacter spp.-inoculated mice demonstrated similar disease penetrance (S1A Fig) with 32.8% (19/58) and 24.1% (7/29) of SFB- and SFB+ mice developing histologically identifiable CRC, respectively (p = 0.562, Chi square). Similarly, when comparing the tumor score alone (S1B Fig; p = 0.43, Kruskal-Wallis ANOVA on ranks), or the overall disease score which also takes into account inflammation and pre-neoplastic epithelial changes (S1C Fig; p = 0.67), no differences were detected between SFB- and SFB+ mice.

No early GM profile found to be predictive of CRC development

To determine whether the GM differed between mice which did or did not eventually develop CAC, data were stratified by time-point and comparisons were visualized and tested via principal coordinate analysis and permutational multivariate analysis (PERMANOVA), respectively. PCoA graphs, based on the weighted Bray-Curtis and Jaccard similarity, of samples collected pre-Helicobacter spp.-inoculation, demonstrated no discernible clustering of CRC+ or CRC- mice in either SFB- (S2A Fig) or SFB+ (S2B Fig) groups. Therefore, no predisposing GM profile was detected for mice which do and do not eventually develop CRC in these two colonies. Similar analyses were performed using data from all early time-points post-inoculation with the same results.

Interactions between sex and SFB influence incidence and severity of CRC

When separated on the basis of sex within the SFB- and SFB+ groups, intriguing interactions were revealed. Firstly, CRC incidence in SFB+ male mice was significantly (p = 0.01, Fisher’s Exact test) reduced compared to SFB+ female mice (Fig 2A). A similar trend, albeit not statistically significant, was seen in SFB- mice, suggesting a possible sex bias in this model. Similarly, overall disease scores (taking into account epithelial changes, inflammation, and tumor size and invasiveness), reflect this pattern of reduced disease severity in SFB+ male mice compared to female counterparts (Fig 2B). Tumor scores follow a similar pattern (Fig 2C). Of particular note, inflammation scores, taken alone, exhibit a significant interaction between sex and SFB (p = 0.004, Two-Way ANOVA), wherein SFB+ female mice have more severe inflammation than SFB- females but SFB+ males have less severe inflammation than SFB- males (Fig 2D). The cause of this polarization of disease severity between male and female mice in response to SFB colonization is as yet unknown, but an area of interest for continued research.

Fig 2 — A) CRC incidence of SFB- and SFB+ male and female *Helicobacter* spp.-inoculated Smad3^-/- mice. Fisher’s Exact Tests within SFB- and SFB+ category (to narrow down an overall chi square test p = 0.0226) revealed significant differences in incidence of CRC between males and females in SFB+ group (p = 0.01) but not within the SFB- group (p = 0.16). B) Overall Disease Scores C) Tumor Scores, and D) Inflammation Scores of male and female mice within the SFB- and SFB+ categories, analyzed via Two-Way ANOVA (*post hoc* Holm-Sidak). Significance and corresponding p values indicated by red lines between different groups. N values for each group indicated in panel A.

Following concerns of a cage effect, a linear mixed modeling statistical analysis was performed on tumor and overall disease severity, with emphasis on cage clustering within the SFB- and SFB+ groups. These analyses found an overall decrease in male tumor (p = 0.0048) and overall disease (p = 0.00089) scores compared to female scores with an intracluster correlation coefficient (ICC) score of 0.076 and 0.074 respectively. The ICC, which spans from 0 to 1, measures the likelihood of a cage or group effect skewing the data. Scores closer to 1 call for the need to analyze each cage or grouping as one individual in statistical analysis.

PCoAs using Bray-Curtis indices (S3 Fig) examine combinations of SFB status, sex, and CRC development on the pre-inoculation timepoint. Taking into account cage groupings in SFB- and SFB+ pre-inoculation PCoAs of mice which did and did not develop CRC, CRC+ mice are well distributed throughout the groups and do not cluster by CRC status or within cage assignments. The GM profiles of SFB+ mice and SFB- mice do show significant differences overall as groups. However, within the SFB+ category, male and female mice GM profiles are not significantly different.

SFB impacts the GM of Smad3^-/- mice during disease development

Stacked bar charts portraying the relative abundance of operational taxonomic units (OTUs) in each group (averaged) provide a subjective overview of the GM over time during disease progression (Fig 3A). Three patterns emerged from pre-inoculation to 2W PI within the SFB-CRC-, SFB-CRC+, SFB+CRC-, and SFB+CRC+ groups. First, the GM of SFB+ mice, regardless of CRC development, remained relatively consistent from pre to 2W post-inoculation when compared to the GM of SFB- mice. Second, colonization with Helicobacter spp. (orange-yellow) peaked at D4 in SFB- mice regardless of CRC development, but was blunted in SFB+ mice. Lastly, microbes in the family Enterobacteriaceae (more specifically resolved as Escherichia-Shigella Escherichia sp.) (light blue) bloomed concurrently with Helicobacter spp. in all groups but SFB+CRC-. S4 Fig contains the full legend for the barcharts provided in Fig 3A.

SFB stabilizes the gut microbiota following Helicobacter spp.-inoculation

Subjectively, SFB- mice appear to have greater community shifts following Helicobacter spp.-inoculation than SFB+ mice. Fig 3B shows a weighted PCoA of Pre and D4 samples from all mice, with lines connecting samples from the same mouse. These distances, representing the dissimilarity between Pre and D4 GM composition of each pair of samples, were used to generate the intra-subject Bray-Curtis dissimilarity index for each mouse using PAST software [28]. Each subject’s Bray-Curtis Dissimilarity index value were then averaged by group and analyzed (Fig 3C). On average, SFB- Pre and D4 time-points were more dissimilar (higher Bray-Curtis dissimilarity value) than Pre and D4 time-points of SFB+ mice (p = 0.023, Mann-Whitney rank sum test), indicating a greater shift in community structure following Helicobacter spp.-inoculation in SFB- mice. In conclusion, despite similar overall penetrance and severity of CRC between SFB- and SFB+ mice, the presence of SFB is associated with a stabilizing effect on the gut microbiota, preventing the dysbiosis often accompanying and contributing to CRC development. No differences in GM stability on the basis of sex were seen in either SFB+ or SFB- group, though there was a trend (p = 0.066, Two-Way ANOVA, post hoc Holm-Sidak) toward greater stability in male mice relative to female mice, regardless of SFB status. No interactions were detected between SFB status and Sex (S5 Fig).

Presence of SFB alters which taxa correlate with disease severity

Spearman’s rank correlations taking into account overall disease score and relative abundance of family (Table 1) and OTU (Table 2) relative abundance in SFB+ and SFB- mice at Pre, D4, and D7 PI were performed to better understand which specific taxa are associated with disease severity. Negative R values are negatively correlated with disease severity, and positive R values are positively correlated with disease severity. Bolded taxa contain an r value stronger than or equal to ±0.5. As with anything involving multiple testing at a high scale, these should be taken with a grain of salt, especially with weak overall r values (averaging around ±3 and ±4). While members such as family Akkermansiaceae and Helicobacteriaceae correlate with disease severity in SFB+ mice only, families associated with mitochondria and Bromus Tectorum (a plant-based sequence likely from feed), which are likely meaningless to CRC development, also appear. However, the complete lack of overlap between correlative taxa between SFB+ and SFB- mice is intriguing, and suggestive that different bacterial taxa are playing a role or responding to disease severity depending on the presence of SFB. In the case of family Akkermansiaceae and, more specifically, Akkermansia uncultured bacterium, relative abundance is positively correlated with disease severity in SFB- mice but negatively correlated with disease severity in SFB+ mice. Notably, in SFB+ mice, family Prevotellaceae, specifically Prevotella 9 uncultured bacterium, and family Desulfovibrionaceae are strongly negatively correlated with disease severity. Family Helicobacteriaceae, which can include other species than the inoculated H. hepaticus and H. bilis, is positively correlated with disease in SFB+ mice at D7. However, at the taxa level, Helicobacter unc. bacterium is positively correlated with SFB- mice while Helicobacter ambiguous taxa is positively correlated with SFB+ mice.

Table 1. Spearman’s ranked correlation of bacterial families at Pre, D4, and D7 in SFB+ and SFB- mice.

Timepoint	GM	Family	R value	P value
Pre	SFB+	Family Desulfovibrionaceae	-0.643	0.000218
Pre	SFB+	Family Prevotellaceae	-0.527	0.00413
Pre	SFB+	Family Ruminococcaceae	-0.45	0.0167
Pre	SFB+	Family Burkholderiaceae	0.467	0.0124
D4	SFB+	Family Prevotellaceae	-0.682	0.0000453
D4	SFB+	Family Rikenellaceae	-0.561	0.00203
D4	SFB+	Family Lachnospiraceae	-0.458	0.0145
D4	SFB+	Family Burkholderiaceae	0.4	0.0349
D4	SFB+	Family Helicobacteriaceae	0.509	0.00588
D4	SFB+	Family Erysipelotrichaceae	0.6	0.00078
D7	SFB+	Family Prevotellaceae	-0.666	0.0000689
D7	SFB+	Family Desulfovibrionaceae	-0.504	0.00558
D7	SFB+	Family Ruminococcaceae	-0.498	0.00619
D7	SFB+	Family Lachnospiraceae	-0.491	0.00712
D7	SFB+	Mitochondria	0.369	0.0487
D7	SFB+	Family Erysipelotrichaceae	0.379	0.0424
D7	SFB+	Family Burkholderiaceae	0.501	0.0059
D7	SFB+	Bromus Tectorum	0.536	0.00288
D7	SFB+	Family Akkermansiaceae	0.55	0.00212
D7	SFB+	Family Helicobacteriaceae	0.551	0.00208
Pre	SFB-	Family Burkholderiaceae	-0.452	0.00405
Pre	SFB-	Clostridiales vadinBB60	-0.403	0.0112
Pre	SFB-	Family Streptococcaceae	0.324	0.0442
Pre	SFB-	Family Bacteroidaceae	0.373	0.0197
D4	SFB-	Family Akkermansiaceae	-0.375	0.00971
D7	SFB-	Family Akkermansiaceae	-0.34	0.017
D7	SFB-	Family Fusobacteriaceae	0.333	0.0197

Open in a new tab

Bacterial families which are significantly correlated with high or low overall disease scores are listed for Pre, D4, and D7 in both SFB- and SFB+ mice. R values and P values are listed side by side. R values range from -1 to +1, with strong negative and positive correlations (respectively), closer to ±1 than 0. Bolded values indicate stronger correlations.

Table 2. Spearman’s ranked correlation of bacterial OTUs at Pre, D4, and D7 in SFB+ and SFB- mice.

Timepoint	GM	OTU	R value	P value
Pre	SFB+	Bilophila unc. Bacterium	-0.643	0.000218
Pre	SFB+	Lachnospiraceae unculture unc.	-0.615	0.000522
Pre	SFB+	Prevotella 9 unc. Bacterium	-0.606	0.000664
Pre	SFB+	Ruminiclostridium 5 unc.	-0.508	0.006
Pre	SFB+	Ruminiclostridium 9 unc.	-0.508	0.006
Pre	SFB+	Lachnospiraceae unc. Taxa	-0.426	0.024
Pre	SFB+	Ruminococcaceae UCG-003 unc.	-0.41	0.0303
Pre	SFB+	[Eubacterium] xylanophilum group	-0.399	0.0357
Pre	SFB+	Lachnospiraceae NC2004 group unc.	-0.392	0.0394
Pre	SFB+	Parasutterella Amb taxa	0.484	0.00924
D4	SFB+	Prevotella 9 unc.Bacterium	-0.725	0.00000002
D4	SFB+	Alistipes unc. Bacterum	-0.555	0.00232
D4	SFB+	Lachnospiraceae unc. taxa	-0.536	0.00345
D4	SFB+	GCA090006657 unc. Bacterium	-0.443	0.0185
D4	SFB+	Lachnospiraceae unc. Unc.	-0.434	0.0212
D4	SFB+	Lachnoclostridium 5 unc.	-0.395	0.0377
D4	SFB+	Helicobacter Ambiguous Taxa	0.00721	0.498
D4	SFB+	Akkermansia unc. Bacterium	0.385	0.0431
D4	SFB+	Parasutterella Amb. Taxa	0.4	0.0349
D4	SFB+	Blautia unc. Bacterium	0.434	0.0212
D4	SFB+	Parasutterella unc. bacterium	0.482	0.00969
D4	SFB+	Faecalibaculum unc. Bacterium	0.592	0.000951
D7	SFB+	Prevotella 9 unc. Bacterium	-0.641	0.00018
D7	SFB+	Lachnospiraceae A2 unc.	-0.625	0.000296
D7	SFB+	incertae sedis unc. Bacterium	-0.592	0.000769
D7	SFB+	Lachnospiraceae unc. Unc.	-0.581	0.00102
D7	SFB+	Ruminiclostridium 9 unc.	-0.569	0.00138
D7	SFB+	Lachnospiraceae UCG-006 unc.	-0.568	0.00139
D7	SFB+	GCA090006657 unc. Bacterium	-0.558	0.00176
D7	SFB+	Lachnospiraceae NC2004 group unc.	-0.55	0.0021
D7	SFB+	Lachnospiraceae 28–4 Unc.	-0.534	0.003
D7	SFB+	Ruminococcaceae unc. Unc.	-0.52	0.004
D7	SFB+	[Eubacterium] xylanophilum group	-0.514	0.00459
D7	SFB+	Lachnospiraceae NK4136 group unc.	-0.512	0.00469
D7	SFB+	Bilophila unc. Bacterium	-0.501	0.00579
D7	SFB+	Lachnospiraceae unc. Taxa	-0.478	0.00892
D7	SFB+	Ruminicoccus 1 unc. Bacterium	-0.478	0.00892
D7	SFB+	Rhodospirillales unc. Bacterium	-0.456	0.0132
D7	SFB+	Lachnospiraceae NK4A136 group	-0.446	0.0155
D7	SFB+	Lachnoclostridium unc. Bacterium	-0.44	0.0173
D7	SFB+	Ruminiclostridium unc. Bacterium	-0.43	0.0199
D7	SFB+	Intestinimonas unc. Bacterium	-0.429	0.0204
D7	SFB+	Oscillibacter unc. Bacterium	-0.411	0.0268
D7	SFB+	Ruminococcaceae UCG-003 unc.	-0.389	0.0372
D7	SFB+	Ruminiclostridium 5 unc.	-0.386	0.0388
D7	SFB+	Escherichia-Shigella unc.	0.412	0.0264
D7	SFB+	Parasutterella amb. taxa	0.496	0.00643
D7	SFB+	Helicobacter Ambiguous Taxa	0.536	0.00284
D7	SFB+	Akkermansia unc. Bacterium	0.55	0.00212
Pre	SFB-	Blautia unc. Bacterium	-0.413	0.0092
Pre	SFB-	Enterococcus Amb. Taxa	-0.363	0.0232
Pre	SFB-	Parasutterella Amb. Taxa	-0.359	0.025
Pre	SFB-	Parasutterella unc. Bacterium	-0.356	0.0261
Pre	SFB-	Odoribacter unc. Bacterium	-0.341	0.034
Pre	SFB-	Roseburia Amb. Taxa	0.331	0.0396
Pre	SFB-	Enterorhabdus unc. Bacterium	0.336	0.0368
Pre	SFB-	Lachnospiraceae unc. unc.	0.339	0.0347
Pre	SFB-	GCA090006657 unc. Bacterium	0.344	0.0323
Pre	SFB-	Intestinimonas unc. Bacterium	0.345	0.0316
Pre	SFB-	Ruminiclostridium 9 unc.	0.35	0.0293
Pre	SFB-	[Eubacterium] corpostanoligene	0.354	0.0274
Pre	SFB-	Lachnospiraceae 28–4 Unc.	0.355	0.0269
Pre	SFB-	Bacteroides unc. Bacterium	0.36	0.0244
Pre	SFB-	Lachnospiraceae unc. taxa	0.366	0.022
Pre	SFB-	Ruminiclostridium 5 unc.	0.373	0.0195
Pre	SFB-	Lachnoclostridium unc. Bacterium	0.387	0.0153
Pre	SFB-	Ruminococcus 1 unc. Bacterium	0.411	0.00954
Pre	SFB-	Oscillibacter unc. Bacterium	0.416	0.00865
Pre	SFB-	Ruminococcaceae UCG-003 unc.	0.451	0.00418
Pre	SFB-	Ruminococcaceae unc. Unc.	0.452	0.00404
Pre	SFB-	Lachnospiraceae A2 unc	0.469	0.00276
D4	SFB-	Akkermansia unc. Bacterium	-0.375	0.00971
D4	SFB-	Ruminiclostridium unc. Bacterium	-0.351	0.0159
D4	SFB-	Lachnospiraceae UCG-001 unc.	-0.31	0.0339
D4	SFB-	Lachnospiraceae A2 unc.	0.325	0.0258
D4	SFB-	Ruminococcaceae UCG-003 unc.	0.34	0.0196
D4	SFB-	Helicobacter unc. Bacterium	0.431	0.00263
D7	SFB-	Akkermansia unc. Bacterium	-0.34	0.017
D7	SFB-	Lachnospiraceae UCG-008 unc. Bacterium	0.312	0.0295
D7	SFB-	Roseburia Amb. Taxa	0.32	0.025
D7	SFB-	Fusobacterium unc. Bacterium	0.321	0.0249
D7	SFB-	Lachnospiraceae A2 unc. Bacterium	0.337	0.00779
D7	SFB-	Helicobacter Unc. bacterium	0.412	0.0034

Open in a new tab

Bacterial OTUs which are significantly correlated with high or low overall disease scores are listed for Pre, D4, and D7 in both SFB- and SFB+ mice. R values and P values are listed side by side. R values range from -1 to +1, with strong negative and positive correlations (respectively), closer to ±1 than 0. Bolded values indicate stronger correlations.

A hypothesis-driven approach would be needed to better understand how these different bacteria are either driving or responding to disease within SFB- and SFB+ contexts, but these data suggest that taxa important to disease development in this model differ based on the presence or absence of SFB.

Relative abundance of Helicobacter spp. at D4 PI predictive of CRC development in SFB- but not SFB+ mice

In addition to the overall temporal uniformity of the GM in the presence or absence of SFB, we were also interested in the influence of SFB on Helicobacter spp. Notably, the proliferation of Helicobacter spp. by D4 differed between SFB- and SFB+ mice (Fig 4A). The relative abundance of Helicobacter spp. in SFB+ mice followed similar kinetics regardless of CRC development (Fig 4A). However, at D4 PI, SFB- mice harbored significantly greater (p = 0.016, Two-Way RM ANOVA) relative abundance of Helicobacter spp. in mice which eventually developed CRC than those which did not (Fig 4A). Therefore, the degree of Helicobacter spp. colonization can be considered predictive of CRC development only in SFB- mice. The diminished Helicobacter spp. colonization in SFB+ mice suggests that SFB provides colonization resistance against Helicobacter spp. and in the context of SFB, Helicobacter spp. colonization may be less important for the development of CRC. When further separated by sex, no differences in Helicobacter spp. kinetics between male and female mice were seen (S6 Fig).

Fig 4 — Family *Enterobacteriaceae* and SFB interact in CRC development. Relative abundance of (A) *Helicobacter* spp. and (B) family *Enterobacteriaceae* (*Escherichia-Shigella Escherichia* sp.) from Pre-inoculation to 3W PI in SFB- and SFB+ *Helicobacter* spp.-inoculated mice. Two-way RM ANOVA performed for SFB- and SFB+ mice separately: like letters denote significant (p < 0.05) differences. P values are as follows: A) SFB- group *a p = 0*.042; b p = 0.005; c p = 0.019; *p = 0.016; **p = 0.024 and SFB+ group *a p = 0*.012; b p = 0.046; c p = 0.031. B) SFB- group ns and SFB+ group *p = 0.048. SFB- group CRC+ (n = 19) and CRC- (n = 38) and SFB+ group CRC+ (n = 7) and CRC- (n = 22).

Family Enterobacteriaceae is predictive of CRC development in SFB+ mice only

Lastly, an OTU annotated to the family Enterobacteriaceae, more specifically resolved as Escherichia-Shigella spp., demonstrated a concurrent bloom with Helicobacter spp. (Fig 4B). From Pre to 3W PI, SFB- mice revealed similar family Enterobacteriaceae kinetics regardless of CRC development, in which family Enterobacteriaceae bloomed at D4 and remained relatively stable over time. However, in SFB+ mice only, family Enterobacteriaceae were significantly (p = 0.048, Two-Way RM ANOVA) more abundant at D4 in mice which eventually developed CRC. This difference in relative abundance in CRC- and CRC+ SFB+ mice only could not only serve as a predictive biomarker, but hint at an interaction between SFB and family Enterobacteriaceae in CRC development, which should be explored further to gauge whether Family Enterobactericeae is interacting with SFB to drive carcinogenesis, or if this family is simply being suppressed in the SFB-CRC- group. Interestingly, when divided by sex in both SFB- and SFB+ groups, female mice demonstrated a greater relative abundance of family Enterobacteriaceae compared to male mice. Statistics were not performed on these data, as there was only one CRC+ male in the SFB+ group (S6B Fig). Linear discriminant analysis effect size (LEfSe) was used to search for biomarkers among groups on Pre and D4 (S7 Fig). Family Enterobacteriaceae relative abundance pulled out as significant within the SFB-CRC- group pre-inoculation, but then was significant within the SFB-CRC+ group at D4 PI. This is puzzling, as the average relative abundance of Family Enterobacteriaceae at D4 within the SFB- group is nearly identical.

Because of this relationship between family Enterobacteriaceae and SFB, we set out to more precisely identify the species contributing to CRC development. Fecal slurries from samples collected D4 PI were streaked onto blood agar plates (BAP) and MacConkey Agar Plates (MAC) in an anaerobic hood. Colonies were identified using matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry. Seven of the eight samples were identified as Escherichia coli, as expected (Fig 5A). One strain of E. coli was isolated and preserved, then restreaked in comparison to ATCC strain 21972. On BAP, the clinical sample was alpha-hemolytic compared to the lab strain, which was beta-hemolytic (Fig 5B). Properties such as these could yield insight to strain-dependent differences in function of E. coli that aren’t readily discernable from 16S sequencing data alone.

Fig 5 — A) MALDI-ToF identification of D4 PI fecal samples. B) Blood Agar and MacConkey Agar plates comparing colony morphology, hemolytic properties, and lactose fermentation of lab strain ATCC 21972 E. *coli* and unknown D4 isolated E.coli strain.

Illumina NextSeq technology was used to sequence these isolates for genome assembly and further analysis for potential virulence factors which may contribute to CRC development. One such target is colibactin, an enzyme already implicated in CRC development due to its ability to cause double-stranded DNA breaks in host epithelial cells. [29] This protein is encoded by the 54 kb biosynthetic gene cluster polyketide synthase (pks) pathogenicity island. [29] These analyses are ongoing and will include other virulence factors, but attempts to map either isolate to the colibactin-encoding pks pathogenicity island was unsuccessful.

Discussion

Although colitis-associated CRC (CAC) accounts for only 1–2% of the total cases of CRC, it results in the death of 15% of IBD patients [5]. This risk increases with the duration of IBD symptoms and severity of inflammation—and due to CAC tumor morphology (flat and multi-focal) and aggressive histology (mucinous adenocarcinomas and signet ring carcinomas) [30], early detection can be challenging. This results in a worse prognosis and higher mortality rate in CACs than sporadic CRCs [5, 6].

Screening programs including frequent surveillance colonoscopies are invasive and don’t address the underlying cause of CAC [31]. An understanding of inciting events early or prior to CAC development is necessary in order to develop preventative strategies and therapeutics to decrease the risk of CRC for IBD-sufferers. Therefore, we conducted a longitudinal study of the gut microbiota in the Smad3^-/- mouse CAC model, focusing on early time-points to better understand the complex relationship of the gut microbiota, chronic inflammation, and tumor development.

We compared the static and dynamic differences of GMs with and without SFB through the course of CRC development. Recently at the forefront of GM studies, SFB’s claim to fame revolves around its immunomodulatory properties, particularly in the induction of Th17-based immunity [16, 32], and its role in modulating the phenotype of models of immune-mediated diseases such as rheumatoid arthritis [19], type 1 diabetes (T1D) [20], and experimental autoimmune encephalomyelitis (EAE) [21]. In a mouse model of colitis, the reduction of SFB and thus Th17 pathway cytokines by early exposure to penicillin was correlated to a reduction in colitis severity [33].

SFB has also been detected in humans, most prominently in children three years of age or younger, as levels decrease below the limit of detection by adulthood [23]. This human variant of SFB results in higher titers of IgA and an up-regulation of Th17 pathways in humans, as in mice [23]. Interestingly, prior to this study, one anecdotal report suggested high numbers (>50 filaments) of SFB-like organisms in histological slides of ileo-cecal valves of patients suffering from UC [34]. Only half of healthy controls contained SFB and in numbers of five filaments or less [34]. Finotti et al also detected SFB via PCR in the terminal ileum of patients with UC [34]. Thus, our hypothesis was that SFB-mediated Th17 responses would exacerbate colitis and the development of CAC.

In the case of the Smad3^-/- CAC model, SFB did not affect overall disease incidence and severity, which was surprising because Th17 levels have been associated with poor CRC prognosis in past studies [35]. However, it impacts the phenotype of this model in more subtle ways. For example, SFB plays a role in stabilization of the GM despite the introduction of inflammatory provocateurs Helicobacter hepaticus and H. bilis, and appears to play a role in colonization resistance despite different intestinal niches. Similar instances of SFB-dependent colonization resistance have been seen in cases of Citrobacter rodentium [16, 36]. Relative abundance of Helicobacter spp. at D4 PI in SFB- mice is predictive of CRC development, but the mouse model relies less heavily on the colonization of Helicobacter spp. trigger if SFB is present. Most intriguingly, only in the presence of SFB does family Enterobacteriaceae, most notably E. coli strains, predict CRC development, while SFB- mice exhibit no diverging pattern of E. coli regardless of eventual CRC status. These data suggest a possible interaction between family Enterobacteriaceae and SFB in disease development and decreased reliance on Helicobacter spp.-colonization than in SFB- mice. The exact role E. coli plays is unclear, though there is evidence in other models of virulence factors such as colibactin contributing to tumor development through double-stranded DNA breakage [37]. The isolation of an α-hemolytic strain of E.coli at D4 PI is intriguing, as invasive species of E. coli, rather than facultative strains, tend to produce virulence factors responsible for α-hemolysis [38], and are often isolated from extraintestinal infections [39] and intraperitoneal infections following breach in intestinal barriers [40]. Thus, we propose a model wherein the classic “driver and passenger” model of bacterial community dynamics during CAC, wherein the reliance of disease changes from the pathobiont “driver” (Helicobacter sp.) to a pathobiont “passenger” (E. coli), depending on the presence or absence of a third bystander (SFB) and its associated colonization resistance against the “driver”.

Thus, while SFB does not modulate the overall incidence or severity of CAC in Helicobacter spp.-inoculated Smad3^-/- mice, we hypothesize that it changes the underlying mechanism of disease development. These mice rely less on Helicobacter spp.- induced dysbiosis than their SFB- counterparts—and may even bring about colonization resistance against this and other mucosa-adherent or invasive bacteria. Because SFB is instrumental in the development of a Th17 compartment in the small intestine lamina propria [16], we propose that the SFB disease mechanism relies more so on an autoimmune Th17 response. Th17 cells produced under conditions of IL-1β and IL-6 exposure with little to no canonical TGF-β signaling (which relies on Smad3 signaling) or with non-canonical TGF-β signaling (which bypasses Smad3) have been reported as pathogenic in EAE models [41, 42]. The lack of Smad3 signaling in this model and the Th17-inducing properties of SFB support this.

Also intriguing are the apparent sex-dependent effects of SFB in the development of CRC. While the greater incidence of CRC in female mice relative to male mice in the absence of SFB did not achieve statistical significance, the sex bias in disease incidence achieved significance in the presence of SFB. Specifically, we speculate that SFB confers a selective protection to male mice, which have reduced disease incidence compared to all other groups. To our knowledge, only one other study has reported a sex-dependent modulation of phenotype by SFB. In 2011, Kriegal et al documented a discordant penetrance of diabetes in NOD mice in their facility in comparison to reports from Jackson Laboratories [20]. However, they found that SFB afforded female mice the same protection from disease development that both SFB+ and SFB- males already benefited from [20].

Several population-based cohort studies found that males were more likely to develop CRC following a diagnosis of IBD than females [43, 44], though IBD and autoimmune diseases are disproportionately skewed toward females [45]. These data, however, do not explain why only male mice are protected by SFB in the Smad3^-/- model. Several studies, however, look to androgen treatment for the down-regulation of inflammation in autoimmune and inflammatory models. Traish et al found that androgen deficiency in men was correlated with higher levels of pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α [46]. Another study found that the gut microbiota from adult male NOD mice conferred protective effects to weanling female NOD mice which was not vertically transmissible to offspring [47]. When investigated further, the male microbiome increased the serum levels of testosterone in those females [47]. Castration of NOD males increased diabetes incidence [48], while exogenous androgen therapies decreased incidence in females [49]. Taking it one step further, Yurkovetskiy documented the ability of SFB to enhance testosterone production and protection against disease incidence selectively in male mice in a model of type-I diabetes [50]. Thus, our current working hypothesis as to how SFB confers protection to only male mice is predicated on a link between testosterone-related changes in gene expression, including decreases in IL-6, a cytokine required for Th17 T cell differentiation, and the male-restricted protection in SFB+ mice. It is possible that SFB is stabilizing the GM and protecting the mucosa from Helicobacter spp.-colonization, yet bringing about CRC through a Th17-driven means, which is abrogated by higher levels of testosterone in male mice. More work must be done to investigate Th17 cytokines in male and female SFB+ mice in the context of the Smad3^-/- model.

In conclusion, these data emphasize the complexity of IBD-driven CRC development, as well as how key members of the GM may subtly alter a mouse model without obvious changes to disease incidence. Because SFB colonization varies between mouse suppliers [16, 17, 20], this threatens the reproducibility of studies and calls for consideration of how microbial variables, both dependent and independent, may act in a variety of contexts. As a matter of translatability, this could also impact how well certain treatments or preventative strategies work in different people in different environments. As a consideration in the design of precision medicine approaches to CAC, the goal of future studies will be to better understand the mechanistic relationship between major players of the GM, inflammatory bowel diseases, and CRC development.

Materials and methods

Animals

Smad3^-/- (129-Smad3^tmPar/J) mice, originally a generous gift from Lillian Maggio-Price, were bred on-site and group-housed in microisolator cages on ventilated racks and provided autoclaved food and water (acidified) ad libitum. Multiple cohorts of mice were used as they were ready, combined into groups based on birthdate, such that inoculation with Helicobacter spp. could occur at 3 weeks of age (weaning). Segmented filamentous bacteria (SFB) groups were generated using breeding pairs colonized with the same GM as the main colony, but that were experimentally inoculated with SFB in order to generate SFB+ offspring. Mice were aged to 14 weeks post-inoculation before euthanasia by CO₂ asphyxiation and secondary cervical dislocation. All animal procedures were approved by the University of Missouri IACUC and performed in accordance with the Guide for the Care and Use of Laboratory Animals, and AVMA Guidelines on Euthanasia.

SFB PCR confirmation

PCR was performed on fecal samples at Pre, D1 and D4 post-inoculation with Helicobacter spp. to confirm presence of SFB. Mice within the SFB+ cohort which tested negative at all of these timepoints were removed from the study. SFB- groups were also tested at random, to confirm the absence of SFB. SFB779 forward (IDT ref: 215274473) and SFB1008 reverse (IDT, ref: 215274472) primers were used in a 25 μL/sample reaction containing 12.875 μL nuclease-free water (Promega, cat: p1193), 2.50 μL 10× PCR buffer + MgCl₂ (Roche, cat: 12161516103), 4 μL 5 mM dNTPs (Roche, cat: 11969064001), 1.25 μL SFB779 forward, 1.25 μL SFB1008 reverse, [51, 52] and 0.125 μL Faststart Taq DNA Polymerase (Roche, cat: 12032953001) mixed with 3 μL DNA. The following parameters were used: 1 cycle of lysis for 3 minutes at 95°C and 40 cycles of denaturation for 15 seconds at 95°C, annealing for 30 seconds at 59°C, and extension for 30 seconds at 72°C.

Bacterial culture

For Helicobacter hepaticus, three blood agar plates per cohort were prepared with 6.0 mL Brucella broth (BD Difco^tm BBL^tm, cat: BD211088) and inoculated with equal portions of a 1 mL frozen aliquot of glycerol (10%)-preserved H. hepaticus. Inoculated plates were incubated at 37°C at a slight tilt in bell jars flushed with CO₂ for 45 seconds and maintained at a pressure of 5 PSI overnight. Upon inspection for purity and robustness under an inverted light microscope, plates of H. hepaticus were passaged into a single flask containing a stir bar and 10% fetal bovine serum (FBS) in Brucella broth, equal to 35 mL total. Flasks were added to a bell jar, flushed as before, and maintained at 5 PSI pressure overnight at 37°C. The final passage was inspected under the inverted microscope for purity and robust growth of bacteria.

For Helicobacter bilis, 1 mL of frozen glycerol stock was transferred to a flask containing 35 mL of Brucella broth supplemented with 10% FBS to, as described above. The bell jars were flushed similarly with CO₂, held at 5 PSI pressure, and incubated at 37°C overnight. Cultures were also inspected via inverted microscope for purity and robust growth of motile bacteria.

Helicobacter spp. inoculation

Pure cultures of Helicobacter hepaticus and H. bilis were combined equally in a 50 mL conical and inverted to mix. Using a curved needle with a ball-tip (i.e., gavage needle), weanling Smad3^-/- mice were administered 0.5 mL of ~10⁸ Helicobacter mixture each by gastric gavage. Sham-inoculated mice are given 0.5 mL of Brucella broth. Each mouse received two inoculations, 24 hours apart.

Fecal sample collection

Mice were placed in individual autoclaved cages absent of substrate and allowed to defecate naturally. Using sterile toothpicks, freshly evacuated fecal pellets were immediately placed into 800 μL of lysis buffer in a 2.0 mL round-bottom tube containing a sterile 0.5 cm-diameter stainless steel ball bearing. To monitor the GM over time, fecal samples were collected prior to the first inoculation (pre), prior to the second inoculation (mid), then one day (D1), D4, D7, two weeks (2W), 3W, 5W, 8W post-inoculation (PI), then at sacrifice (14W).

Tissue sample collection

Following euthanasia at 14W, mice were necropsied and their colon, cecum, and ileum removed as one continuous piece. The most aboral fecal pellet was removed from each mouse and added to a round bottomed tube as described before. Cecal contents were collected similarly, using flame sterilized scissors to cut open the cecum and a sterile toothpick to gather up the contents. The tissue was flushed with saline then fixed in 10% formalin. The entire colon was embedded in paraffin and 5 μm-thick longitudinal sections were prepared and stained with hematoxylin and eosin for histological examination and lesion scoring.

DNA extraction

DNA extraction was performed using a two-stage process first described by Yu et al [53] and adapted for murine samples by Ericsson et al [2]. Briefly, fecal DNA was extracted using an ammonium acetate/isopropanol protocol first described by Yu and Morrison [53]. The pellet was resuspended in Tris-EDTA buffer and purified over a DNeasy column using the manufacturer’s instructions for DNA extraction from cells using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, cat: 69506). The DNA was eluted in EB Buffer rather than the supplied AE buffer. Final DNA concentrations were quantified using a Qubit 2.0 fluorometer and Qubit dsDNA BR Assay Kit (Invitrogen, cat:Q32853).

16S rDNA library preparation and sequencing

Library construction and sequencing was performed in a 96-well multiplexed format by the University of Missouri DNA Core as described previously [14, 54]. In brief, dual-indexed universal primers F515/R806, flanked by Illumina adaptor sequences, were used to construct amplicons of the V4 hypervariable regions of 16s rRNA gene. Amplicon libraries were pooled and sequenced on the Illumina MiSeq platform and the V2 chemistry [55].

Informatics analysis

Informatics were performed by the University of Missouri Informatics Research Core Facility. FLASH (Fast Length Adjustment of SHort reads) software was used to merge DNA sequences [56]. Reads were truncated if the base quality was less than 31 and removed if total length was less than the expected 292 basepairs [54, 55]. Primers on both ends of the contigs were removed with cutadapt, [57] and sequences initially lacking primers on one or both ends were deleted. Contigs with expected errors <0.5 were retained and trimmed for quality using the USEARCH fastq_filter command then clipped to 248 bases each [58]. Samples were de-multiplexed using Qiime v1.9 (split_libraries_fastq.py) and concatenated into a single file [59]. Samples were clustered into OTUs, based on 97% similarity cut-off using the uparse method [60], then assigned taxonomy using BLAST against SILVA database v132 (http://www.arb-silva.de) of 16S rRNA sequencing and taxonomy [61].

Histopathology

H&E-stained slides were analyzed by a trained veterinary pathologist, blinded to treatment groups, and given colonic lesion scores based on epithelial changes, inflammation, and tumor size and invasiveness as follows:

Epithelial Changes: Hyperplasia/Dysplasia (1–5), Longitudinal Extent (0–4), Total Epithelial Score (Hyperplasia/Dysplasia Score × Longitudinal Extent Score).

Inflammation: Inflammatory Severity (0–3), Longitudinal Extent (0–4), and Total Inflammatory Score (Inflammatory Severity × Longitudinal Extent).

Tumor Score: Tumor Size (#10× fields/tumor), Invasiveness (1–3), and Total Tumor Score (Tumor Size × Invasiveness)

Overall Disease Score: Total Epithelial Changes Score + Total Inflammation Score + Total Tumor Score

Anaerobic bacterial culture and identification

Day 4 PI fecal samples were collected from SFB+ and SFB- Helicobacter-inoculated mice into 800 μL sterile water in a sterile 2 mL round-bottom tube. Samples were lysed via TissueLyser and taken into the anaerobic hood. Each sample was streaked onto Blood Agar (BAP) and MacConkey Agar (MAC) plates. The two distinct morphologies isolated on MAC plates were re-streaked for additional purity and frozen back as stock in 10% glycerol. The BAP were examined via matrix-assisted laser desorption-ionization time-of-flight (MALDI-ToF) mass spectrometry (Bruker Microflex LT MALDI-TOF Mass Spectrometer) for strain identification (IDEXX BioAnalytics) using the Bruker Daltonics Database (BDAL).

E.coli Isolate genome sequencing

The two separate E. coli isolates were submitted to the MU DNA Core for sequencing on the Illumina NextSeq. The University of Missouri Informatics Research Core Facility mapped isolate reads against AM229678 EMBL database pks sequence data using bowtie2 (version 2.3.4.3). Samtools (version 0.1.19-44428cd) was used to create a table of read depth for each position in the pks reference, which was compared visually with data found at https://www.ebi.ac.uk/ena/data/view/AM229678&display=text to identify annotated regions of the pks reference.

Statistical analysis

Histological scoring was performed as described above and paired with the longitudinal GM data for each mouse. Incidence was determined based on presence/absence of tumor in the colon and categorized by SFB status then further divided by sex within each category. Chi-square and Chi-square further delineated using individual Fisher’s Exact tests respectively, measured significance along those two groupings. Tumor scores, inflammation scores, and overall disease scores were similarly separated by SFB status and then further divided by sex within these categories. Kruskal-Wallis one-way ANOVA on ranks and Two-Way ANOVA tests (post hoc Holm-Sidak) were used respectively to determine statistical differences between groups.

Multivariate analysis including generation of Principal Coordinate Analysis (PCoA), loading plots, and PERMANOVA statistical analysis were performed using PAleontological STatistics (PAST) [28]. Separate PCoAs, using Bray-Curtis and Jaccard diversity indices, were generated to compare CRC+ and CRC- animals in SFB+ and SFB- groups at various timepoints, including pre-inoculation and D4 post-inoculation.

Overall GM community shifts between corresponding Pre and D4 samples of SFB+ and SFB- mice were analyzed using the Bray-Curtis dissimilarity Index using PAST [28]. The Mann-Whitney Rank Sum test determined statistical significance between groups. These groups were further divided by sex within SFB group and analyzed using a Two-Way ANOVA (post hoc Holm-Sidak).

Bacterial kinetics of Helicobacter spp. (both Helicobacter OTUs detected were averaged together into one value per sample) and family Enterobacteriaceae were generated by taking the averages of relative abundances of each OTU from Pre to 3W post-inoculation timepoints, using Microsoft Excel for SFB- and SFB+ groups. Two-way Repeated Measures ANOVA (post hoc Bonferroni), performed separately for SFB- and SFB+ groups, determined statistical significance and interactions between CRC development, timeline, and relative abundance of the target OTU. Kinetics were further divided on basis of sex, but stats were not performed as animal numbers per group were too low.

Linear discriminant analysis effect size (LEfSE) [62] was performed at the OTU level for D1 and D4 for SFB-CRC-, SFB-CRC+, SFB+CRC-, and SFB+CRC+ groups. The lowest number of counts per OTU was set at 12.

Spearman rank correlations were performed using SigmaPlot version 14.0. In short, SFB+ and SFB- correlations were performed separately for Pre, D4, and D7 timepoints at the OTU and Family level, using ranked overall scores. The R values for OTUs and families with a p value <0.05 were recorded.

To account for potential clustering effects of multiple animals being housed in the same cage, linear mixed effects models generated by the lme4 package were used with cage number as a random effect [63]. Models with sex and SFB status as independent variables were evaluated, as well as models with multiplicative interactions between sex and SFB status. The Car package used to generate P values from lme4-generated mixed modeling data, using the Anova function [64].

Supporting information

S1 Fig. SFB does not impact overall penetrance or severity of CAC.

Penetrance of CRC a), Tumor Scores b), and Overall Disease Scores c) in SFB- and SFB+ groups. Chi Square a) and Kruskal-Wallis One Way ANOVA on Ranks (b and c) performed.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S2 Fig. No early GM profile found to be predictive of CRC development.

Principal Component Analysis (PCoA) graphs utilizing the a) Bray-Curtis and b) Jaccard diversity indices of pre-inoculation timepoints for SFB- and SFB+ cohorts which did and did not develop CRC. PERMANOVA (permutation number = 9999) on each PCoA between CRC+ and CRC- groups. A) SFB- Bray-Curtis p = 0.1626; SFB+ Bray-Curtis p = 0.5162 B) SFB- Jaccard p = 0.1398; SFB+ Jaccard p = 0.1161.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S3 Fig. Examining the effects of cage and sex on CRC.

PCoAs using Bray-Curtis indices of a) CRC and SFB and Sex and SFB categorized pre-inoculation samples and b) SFB- and SFB+ mice categorized by cage. One-way PERMANOVA determined statistical differences in A between SFB+CRC+ mice and SFB- mice regardless of CRC fate (SFB-CRC- p = 0.0006; SFB-CRC+ p = 0.0204). Using Bonferroni-corrected p values, with a permutation number of 9999, Male SFB+ mice were statistically different from both male (p = 0.0114) and female (p = 0.0006) SFB- mice but not female SFB+ mice (p = 0.1758) at Pre-inoculation timepoint. Pairwise comparisons included below each PCoA.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S4 Fig. Accompanying figure legend to Fig 3A.

Corresponding OTUs to each segment of the barcharts shown on Fig 3A.

(TIF)

Click here for additional data file.^{(4.8MB, tif)}

S5 Fig. Bray-Curtis dissimilarity Index examining total GM shifts between female and male mice within the SFB- and SFB+ groups from Pre-inoculation to D4 PI.

Two-Way Anova (post hoc Holm-Sidak) test performed. Only the overall differences between SFB+ and SFB- was significant (p = 0.015).

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S6 Fig. Helicobacter spp. and Family Enterobacteriaceae kinetics between male and female mice.

Relative abundance of a) Helicobacter spp. and b) Family Enterobacteriaceae in male and female SFB- and SFB+ mice which did and did not develop CRC. No stats were performed due to a low n.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S7 Fig. LEfSe analysis at early timepoints.

Linear discriminant analysis effect size (LEfSe) on a) Pre-inoculation and b) D4 post-inoculation in SFB+CRC-, SFB+CRC+, SFB-CRC+, and SFB-CRC- groups.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

Acknowledgments

We would like to acknowledge the MU DNA Core and MU Informatics Research Core facilities for their invaluable services in sequencing and analyzing the 16S rRNA data.

Data Availability

Data may be found in the SRA database under bioproject ID PRJNA548523. The reviewer link is as follows: https://dataview.ncbi.nlm.nih.gov/object/PRJNA548523?reviewer=9f68h3l705qbmaurmmg3r0b8hu.

Funding Statement

C.F. received funding (Grant#: U42 OD010918) from National Institutes of Health (NIH), Office of the Director (https://www.nih.gov/institutes-nih/nih-office-director). A.E. received funding (grant#: K01 OD019924) from NIH, Office of the Director (https://www.nih.gov/institutes-nih/nih-office-director). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1.Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67(3):177–93. 10.3322/caac.21395 [DOI] [PubMed] [Google Scholar]
2.Ericsson AC, Myles M, Davis W, Ma L, Lewis M, Maggio-Price L, et al. Noninvasive detection of inflammation-associated colon cancer in a mouse model. Neoplasia. 2010;12(12):1054–65. 10.1593/neo.10940 [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Lakatos P-L, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World journal of gastroenterology. 2008;14(25):3937–47. Epub 07/07. 10.3748/wjg.14.3937 . [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14 e5. 10.1053/j.gastro.2010.01.058 . [DOI] [PubMed] [Google Scholar]
5.Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:1–5. 10.1046/j.1365-2036.18.s2.2.x . [DOI] [PubMed] [Google Scholar]
6.Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: A nationwide Japanese study. Inflammatory Bowel Diseases. 2011;17(3):802–8. 10.1002/ibd.21365 [DOI] [PubMed] [Google Scholar]
7.de Vos WM, de Vos EAJ. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutrition Reviews. 2012;70(suppl_1):S45–S56. 10.1111/j.1753-4887.2012.00505.x [DOI] [PubMed] [Google Scholar]
8.Hart ML, Ericsson AC, Franklin CL. Differing Complex Microbiota Alter Disease Severity of the IL-10−/− Mouse Model of Inflammatory Bowel Disease. Frontiers in Microbiology. 2017;8(792). 10.3389/fmicb.2017.00792 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Fichtner-Feigl S, Kesselring R, Strober W. Chronic inflammation and the development of malignancy in the GI tract. Trends in immunology. 2015;36(8):451–9. Epub 07/18. 10.1016/j.it.2015.06.007 . [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer research. 2006;66(2):828–38. 10.1158/0008-5472.CAN-05-2448 . [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Fox JG. Helicobacter bilis: bacterial provocateur orchestrates host immune responses to commensal flora in a model of inflammatory bowel disease. Gut. 2007;56(7):898–900. 10.1136/gut.2006.115428 . [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, et al. Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut. 2007;56(7):934–40. Epub 12/01. 10.1136/gut.2006.099242 . [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Ericsson AC, Davis JW, Spollen W, Bivens N, Givan S, Hagan CE, et al. Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PloS one. 2015;10(2):e0116704–e. 10.1371/journal.pone.0116704 . [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Ericsson AC, Akter S, Hanson MM, Busi SB, Parker TW, Schehr RJ, et al. Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. Oncotarget. 2015;6(32):33689–704. 10.18632/oncotarget.5604 . [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Klaasen HL, Van der Heijden PJ, Stok W, Poelma FG, Koopman JP, Van den Brink ME, et al. Apathogenic, intestinal, segmented, filamentous bacteria stimulate the mucosal immune system of mice. Infection and immunity. 1993;61(1):303–6. . [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485–98. 10.1016/j.cell.2009.09.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Ivanov II, Frutos RdL, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell host & microbe. 2008;4(4):337–49. 10.1016/j.chom.2008.09.009 . [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Denning TL, Norris BA, Medina-Contreras O, Manicassamy S, Geem D, Madan R, et al. Functional specializations of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization. J Immunol. 2011;187(2):733–47. 10.4049/jimmunol.1002701 [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–27. Epub 2010/07/14. 10.1016/j.immuni.2010.06.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Kriegel MA, Sefik E, Hill JA, Wu H-J, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proceedings of the National Academy of Sciences. 2011;108(28):11548–53. 10.1073/pnas.1108924108 [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4615–22. 10.1073/pnas.1000082107 [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Caselli M, Tosini D, Gafa R, Gasbarrini A, Lanza G. Segmented filamentous bacteria-like organisms in histological slides of ileo-cecal valves in patients with ulcerative colitis. Am J Gastroenterol. 2013;108(5):860–1. Epub 2013/05/07. 10.1038/ajg.2013.61 . [DOI] [PubMed] [Google Scholar]
23.Chen B, Chen H, Shu X, Yin Y, Li J, Qin J, et al. Presence of Segmented Filamentous Bacteria in Human Children and Its Potential Role in the Modulation of Human Gut Immunity. Front Microbiol. 2018;9:1403 10.3389/fmicb.2018.01403 [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Ericsson AC, Turner G, Montoya L, Wolfe A, Meeker S, Hsu C, et al. Isolation of segmented filamentous bacteria from complex gut microbiota. Biotechniques. 2015;59(2):94–8. Epub 2014/01/01. 10.2144/000114319 . [DOI] [PubMed] [Google Scholar]
25.Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr. 1999;69(5):1046S–51S. Epub 1999/05/08. 10.1093/ajcn/69.5.1046s . [DOI] [PubMed] [Google Scholar]
26.Ericsson AC, Hagan CE, Davis DJ, Franklin CL. Segmented filamentous bacteria: commensal microbes with potential effects on research. Comp Med. 2014;64(2):90–8. Epub 2014/03/29. [PMC free article] [PubMed] [Google Scholar]
27.Snel J, Hermsen CC, Smits HJ, Bos NA, Eling WM, Cebra JJ, et al. Interactions between gut-associated lymphoid tissue and colonization levels of indigenous, segmented, filamentous bacteria in the small intestine of mice. Can J Microbiol. 1998;44(12):1177–82. Epub 1999/05/29. 10.1139/cjm-44-12-1177 . [DOI] [PubMed] [Google Scholar]
28.Hammer ØH, David A. T.; Ryan, Paul D. PAST: Paleontological statistics software package for education and data analysis. Palaeontologia Electronica. 2001;4(1):9. [Google Scholar]
29.Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313(5788):848–51. Epub 2006/08/12. 10.1126/science.1127059 . [DOI] [PubMed] [Google Scholar]
30.Ording AG, Horváth-Puhó E, Erichsen R, Long MD, Baron JA, Lash TL, et al. Five-Year Mortality in Colorectal Cancer Patients with Ulcerative Colitis or Crohn's DiseaseA Nationwide Population-based Cohort Study. Inflammatory Bowel Diseases. 2013;19(4):800–5. 10.1097/MIB.0b013e3182802af7 [DOI] [PubMed] [Google Scholar]
31.Roncucci L, Mariani F. Prevention of colorectal cancer: How many tools do we have in our basket? Eur J Intern Med. 2015;26(10):752–6. 10.1016/j.ejim.2015.08.019 . [DOI] [PubMed] [Google Scholar]
32.Yang Y, Torchinsky MB, Gobert M, Xiong H, Xu M, Linehan JL, et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature. 2014;510(7503):152–6. 10.1038/nature13279 [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Jin S, Zhao D, Cai C, Song D, Shen J, Xu A, et al. Low-dose penicillin exposure in early life decreases Th17 and the susceptibility to DSS colitis in mice through gut microbiota modification. Sci Rep. 2017;7:43662 10.1038/srep43662 [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Finotti A, Gasparello J, Lampronti I, Cosenza LC, Maconi G, Matarese V, et al. PCR detection of segmented filamentous bacteria in the terminal ileum of patients with ulcerative colitis. BMJ Open Gastroenterol. 2017;4(1):e000172 10.1136/bmjgast-2017-000172 [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Yoshida N, Kinugasa T, Miyoshi H, Sato K, Yuge K, Ohchi T, et al. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells). Annals of Surgical Oncology. 2016;23(3):919–27. 10.1245/s10434-015-4923-3 [DOI] [PubMed] [Google Scholar]
36.Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Medicine. 2008;14:282 10.1038/nm1720 https://www.nature.com/articles/nm1720#supplementary-information. [DOI] [PubMed] [Google Scholar]
37.Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut microbes. 2014;5(5):675–80. 10.4161/19490976.2014.969989 . [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Skals M, Jorgensen NR, Leipziger J, Praetorius HA. Alpha-hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis. Proc Natl Acad Sci U S A. 2009;106(10):4030–5. Epub 2009/02/20. 10.1073/pnas.0807044106 [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Cavalieri SJ, Bohach GA, Snyder IS. Escherichia coli alpha-hemolysin: characteristics and probable role in pathogenicity. Microbiol Rev. 1984;48(4):326–43. Epub 1984/12/01. [DOI] [PMC free article] [PubMed] [Google Scholar]
40.May AK, Gleason TG, Sawyer RG, Pruett TL. Contribution of Escherichia coli alpha-hemolysin to bacterial virulence and to intraperitoneal alterations in peritonitis. Infect Immun. 2000;68(1):176–83. Epub 1999/12/22. 10.1128/iai.68.1.176-183.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Ghoreschi K, Laurence A, Yang X-P, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature. 2010;467:967 10.1038/nature09447 https://www.nature.com/articles/nature09447#supplementary-information. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, et al. Induction and molecular signature of pathogenic TH17 cells. Nature immunology. 2012;13(10):991–9. Epub 09/09. 10.1038/ni.2416 . [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Jewel Samadder N, Valentine JF, Guthery S, Singh H, Bernstein CN, Wan Y, et al. Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Digestive Diseases and Sciences. 2017;62(8):2126–32. 10.1007/s10620-016-4435-4 [DOI] [PubMed] [Google Scholar]
44.Lee SM, Kim N, Son HJ, Park JH, Nam RH, Ham MH, et al. The Effect of Sex on the Azoxymethane/Dextran Sulfate Sodium-treated Mice Model of Colon Cancer. J Cancer Prev. 2016;21(4):271–8. 10.15430/JCP.2016.21.4.271 [DOI] [PMC free article] [PubMed] [Google Scholar]
45.Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front Immunol. 2018;9:2279 10.3389/fimmu.2018.02279 [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Traish A, Bolanos J, Nair S, Saad F, Morgentaler A. Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. J Clin Med. 2018;7(12). 10.3390/jcm7120549 . [DOI] [PMC free article] [PubMed] [Google Scholar]
47.Markle JG, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes. 2014;5(4):485–93. 10.4161/gmic.29795 . [DOI] [PubMed] [Google Scholar]
48.Makino S, Kunimoto K, Muraoka Y, Katagiri K. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu. 1981;30(2):137–40. 10.1538/expanim1978.30.2_137 . [DOI] [PubMed] [Google Scholar]
49.Fox HS. Androgen treatment prevents diabetes in nonobese diabetic mice. J Exp Med. 1992;175(5):1409–12. 10.1084/jem.175.5.1409 [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39(2):400–12. Epub 2013/08/27. 10.1016/j.immuni.2013.08.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Urdaci MC, Regnault B, Grimont PA. Identification by in situ hybridization of segmented filamentous bacteria in the intestine of diarrheic rainbow trout (Oncorhynchus mykiss). Res Microbiol. 2001;152(1):67–73. Epub 2001/04/03. 10.1016/s0923-2508(00)01169-4 . [DOI] [PubMed] [Google Scholar]
52.Snel J, Heinen PP, Blok HJ, Carman RJ, Duncan AJ, Allen PC, et al. Comparison of 16S rRNA sequences of segmented filamentous bacteria isolated from mice, rats, and chickens and proposal of "Candidatus Arthromitus". Int J Syst Bacteriol. 1995;45(4):780–2. 10.1099/00207713-45-4-780 . [DOI] [PubMed] [Google Scholar]
53.Yu Z, Morrison M. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques. 2004;36(5):808–12. 10.2144/04365ST04 . [DOI] [PubMed] [Google Scholar]
54.Hart ML, Ericsson AC, Lloyd KCK, Grimsrud KN, Rogala AR, Godfrey VL, et al. Development of outbred CD1 mouse colonies with distinct standardized gut microbiota profiles for use in complex microbiota targeted studies. Sci Rep. 2018;8(1):10107 Epub 2018/07/06. 10.1038/s41598-018-28448-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108 Suppl 1:4516–22. 10.1073/pnas.1000080107 [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957–63. 10.1093/bioinformatics/btr507 [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011. 2011;17(1):3 Epub 2011-08-02. 10.14806/ej.17.1.200 [DOI] [Google Scholar]
58.Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1. 10.1093/bioinformatics/btq461 . [DOI] [PubMed] [Google Scholar]
59.Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. Current protocols in bioinformatics. 2011;Chapter 10:Unit10.7-.7. 10.1002/0471250953.bi1007s36 . [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nature Methods. 2013;10:996 10.1038/nmeth.2604 https://www.nature.com/articles/nmeth.2604#supplementary-information. [DOI] [PubMed] [Google Scholar]
61.Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Research. 2012;41(D1):D590–D6. 10.1093/nar/gks1219 [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60 Epub 2011/06/28. 10.1186/gb-2011-12-6-r60 [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015. 2015;67(1):48 Epub 2015-10-07. 10.18637/jss.v067.i01 [DOI] [Google Scholar]
64.Weisberg JFaS. An R Companion to Applied Regression. Third ed Thousand Oaks, CA: Sage Publications; 2019. [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0236595.r001

Decision Letter 0

Hiroyasu Nakano

22 Apr 2020

PONE-D-20-08853

Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development.

PLOS ONE

Dear Dr. Ericsson

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Both reviewers feel that the study is potentially interesting, however, they also feel that the results presented here are not sufficient to support the authors' conclusion. Moreover, one reviewer has also a serious concern of the statistical methods used in the study.

==============================

We would appreciate receiving your revised manuscript by June 21, 2020. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Hiroyasu Nakano, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"This work was funded in part by NIH grants K01 OD019924 and U42 OD010918. A.W. was supported by a University of Missouri Life Science Fellowship."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"Funding for this research was provided as follows:

C.F. received funding (Grant#: U42 OD010918) from

NIH, Office of the Director (https://www.nih.gov/institutes-nih/nih-office-director)

A.E. received funding (grant#: K01 OD019924 ) from NIH, Office of the Director (https://www.nih.gov/institutes-nih/nih-office-director)

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Wolfe et al. reported in this manuscript that CRC incidence, disease scores, tumor scores, and inflammation scores after Helicobacter spp. inoculation in Smad3-/- mice were significantly reduced in male mice compared to female mice only when SFB was inoculated. In addition, the authors showed that SFB inhibited colonization of Helicobacter spp. Relative abundance of Helicobacter spp. was predictive of CRC development in SFB- mice whereas E. Coli were significantly more abundant in mice which eventually developed CRC in SFB+ mice. Although the study was well planned and revealed interacting phenomena regarding intestinal bacterial colonization during CRC development in the Helicobacter spp-Smad3-/- mouse model, it was too descriptive. More rigorous examination needs to be performed. Specific comments are below.

1. Immune cell population and activation including expansion of Th17 cells and production of Th17 cytokines need to be tested in male and female mice in the presence/absence of SFB.

2. There were no differences in GM stability on the basis of sex in either SFB+ or SFB- mice (Fig. S4). Since the authors showed that CRC development was reduced in male SFB+ mice, this observation seems to contradict with the conclusion “Relative abundance of Helicobacter spp. was predictive of CRC development in SFB- mice”.

Minor comment

3. This reviewer suggests to present representative pictures of intestinal histology in addition to quantified results presented in the manuscript.

Reviewer #2: Wolfe et al., described the protective role of SFB on colorectal cancer (CRC) of smad3-/- male mice. However, it is unclear that the interactions among three bacteria, SFB, Helicobacter and E. coli are relevant to the disease severity of CRC, because key and comprehensive analyses are missing in this manuscript. More detailed comments are provided below:

Comments:

1. It is unclear what Figure 3a shows. The text says " relative abundance of operational taxonomic units (OTUs)" (Line 169), but the figure has " Enterobacteriaceae" (family) and "Helicobacter spp." (genus), implying that the analysis is at family or genus level. Which taxonomic level did the authors use, OTU@>97%, genus, or family? If it is possible, please use yellow and blue to make the highlighted taxons clearer in the panel. Moreover, description of other OTUs is missing. I would like to request the supplemental table of OTU abundance of individual samples to review and judge the results of figures in this manuscript.

2. For the conclusion "Three patterns emerged from pre-inoculation to 2W PI within the SFB-CRC-, SFB-CRC+, SFB+CRC-, and SFB+CRC+ groups. First, the GM of SFB+ mice, regardless of CRC development, remained relatively consistent from pre to 2W post inoculation when compared to the GM of SFB- mice. Second, colonization with Helicobacter spp. peaked at D4 in SFB- mice regardless of CRC development, but was blunted in SFB+ mice. Lastly, unresolved microbes in the family Enterobacteriaceae bloomed concurrently with Helicobacter spp. in all groups but SFB+CRC-." (Lines 170 - 176), the authors should perform multiple statistical analyses including LEfSe and FDR.

3. The conclusion "Subjectively, SFB- mice appear to have greater community shifts following Helicobacter spp.-inoculation than SFB+ mice. " (Lines 188 - 190) and following statement require the result of statistical analysis.

4. "On average, SFB- Pre and D4 time-points were more dissimilar than Pre and D4 time-points of SFB+ mice (p = 0.023, Mann-Whitney rank sum test)," (Line 191 to 193). The authors should show medians but not averages as the data was non-parametric as they used Mann-Whitney rank sum test. The comparison also needs controls, Bray-Curtis indexes of internal Pre and D4, because the difference might simply reflect the internal variations of Pre or D4, and it must be multiple comparison test and another test other than Mann-Whitney is required. I have a similar concern on Figure S4.

5. The analysis of the sections "Relative Abundance of Helicobacter spp. at D4 PI predictive of CRC development in SFB- but not SFB+ mice." and Family Enterobacteriaceae and SFB interact in CRC development is biased for particular bacteria. The authors should perform Spearman ranking test of all (from higher to lower) taxons with CRC levels. This is the most critical point for the science of this manuscript.

6. "Colonies were identified using matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF)

mass spectrometry. Seven of the eight samples were identified as Escherichia coli, as expected (Figure

5A)" Because Figure 5A too much simplified the result of MALDI-TOF, the authors should attach the supplemental tables of identified bacterial molecules and describe which database was used for identification of the molecules. Morerover, the authors should describe justification for the reason why they used mass spec as genome sequencing of isolates gives more accurate and detailed results with low cost.

7. According to the abundance of Enterobacteriaceae in Figures 3a and 4, the fact that the result of Figure 4a showed the dominance of E. coli, suggests cloning bias of bacterial isolates. This raises the concern about bias in the conclusion.

8. What does the finding on hemolytic features of one E. coli strain (Fig, 5b) mean? Is this associated with the conclusions of this manuscript?

Minor comments:

9. The figure legend is missing. How many mice were used in the experiments for each panel? What are 19/57 and 7/29? The text says "32.8% (19/58) and 40.5% (15/37)" (Lines 116 and 117). Fig. S1a needs the visible Y axis.

10. The weaning day in Fig.1 Moreover, "two inoculations (M), then Day 1 (Day 1)" (Line 104) must be " two inoculations (mid), then Day 1 (D1)". I could not find "PI" in Fig. 1 although the text says "post-inoculation (PI)" as a label.

11. The p values and the permutation number of PERMANOVA were missing in the text and/or Figures S2 and S3.

12. Figure 3c shows bars and SD. I believe that the Bray-Curtis index values are non-parametric as the authors used Mann-Whitney test. Please use a box and whisker plot in Figure 3c. Similarly, some data of Figure 2 seem to be non-parametric, and presentation with means and SD is inappropriate. Please use box and whisker plots in Figure 2.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Jul 24;15(7):e0236595. doi: 10.1371/journal.pone.0236595.r002

Author response to Decision Letter 0

18 Jun 2020

To whom it may concern,

We sincerely appreciate the careful and thorough reading of our manuscript (PONE-D-20-08853) titled, “Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development” by the reviewers. They have made excellent suggestions and we have revised the manuscript accordingly. Below, we list each of the reviewers’ comments and suggestions individually, followed by our specific responses in bold text.

1. Immune cell population and activation including expansion of Th17 cells and production of Th17 cytokines need to be tested in male and female mice in the presence/absence of SFB.

Thank you for this excellent suggestion. The purpose of this study was to examine the role of the gut microbiota longitudinally through the course of CRC development, to delineate bacterial taxa associated with differential susceptibility to CAC initiation, or differential disease severity (i.e., progression). Thus, CAC was our primary outcome measure for this study. While we intend to validate the expansion and function of several leukocyte subsets and relevant cytokines in future studies, it was beyond the scope of the current studies. While IL-17 is a logical downstream effector molecule induced by SFB, previous data from our lab suggest that CAC in Smad3 mice is driven by innate immune responses, while Helicobacter induces Th1 responses and mucosal barrier defects. Thus, our intent is to perform single cell RNAseq using GI tissue, MLN, and spleen of select groups of mice identified in this and a separate study.

The stability of the GM is based on community-wide changes in beta-diversity, and increases or decreases in abundance of individual taxa, even dominant ones like Helicobacter, do not necessarily correlate with overall stability. Indeed, we respectfully maintain that the relative abundance of Helicobacter spp. is predictive of CRC development in SFB negative mice, but not SFB+ mice. There was no disease score difference in SFB- mice by sex, thus we do not believe this to be a contradiction. We apologize in advance if we have misunderstood the Reviewer’s comment and welcome further discussion if this is the case.

Minor comment

3. This reviewer suggests to present representative pictures of intestinal histology in addition to quantified results presented in the manuscript.

The reviewer makes an excellent suggestion and we have added a representative photo as Fig 1Bi and ii, and shifted the original Fig 1B to Fig 1C. Figure legends and text have been updated to reflect this.

This study was originally performed to determine the effect of SFB, a common commensal in the mouse gut with potent immunomodulatory capacity, on the CAC phenotype, as its impact has been observed and studied in other disease models. The observations reported in the current study (i.e., interactions between Helicobacter spp., family Enterobacteriaceae, and SFB) were somewhat unexpected and, admittedly, somewhat observational. Nonetheless, we believe that our findings are very informative in terms of gut microbial ecology during disease initiation and progression as few (if any) studies have provided robust longitudinal data throughout all stages of CAC. Many of the ostensible interactions reported in the current data are of great interest to us, and will be tested prospectively in future studies to better determine causality and the mechanistic relevance to disease.

While we would maintain that family Enterobacteriaceae and Helicobacter spp. behave differently within the context of SFB+ mice versus SFB- mice, we completely understand the Reviewer’s concern and have adjusted the verbiage in the manuscript to avoid over-interpretation.

Comments:

1. It is unclear what Figure 3a shows. The text says " relative abundance of operational taxonomic units (OTUs)" (Line 169), but the figure has " Enterobacteriaceae" (family) and "Helicobacter spp." (genus), implying that the analysis is at family or genus level. Which taxonomic level did the authors use, OTU@>97%, genus, or family? If it is possible, please use yellow and blue to make the highlighted taxa clearer in the panel. Moreover, description of other OTUs is missing. I would like to request the supplemental table of OTU abundance of individual samples to review and judge the results of figures in this manuscript.

We appreciate the reviewer’s suggestion and apologize for the confusion. Family Enterobacteriaceae, now highlighted in light blue, comprised solely Escherichia-Shigella, Escherichia sp. The manuscript has been updated to specify this. Family Enterobactericeae is used as an umbrella term due to poor sequencing resolution between species within this family.

Helicobacter spp., now highlighted in orange-yellow, comprised Helicobacter uncultured bacterium and Helicobacter Ambiguous taxa. The vast majority (visible portion) of the orange-yellow bar of the barchart represents Helicobacter ambiguous taxa. The linecharts in Fig 4a and Fig S4a represent sums of both of the Helicobacters spp. present.

Arrows have been added to the figure to point out the light blue and orange-yellow portions within the bar charts.

We have also included the color-coded list of other OTUs present within the barchart as a new Fig S3, and similar Supplemental Figures have been relabeled.

We appreciate the reviewer’s suggestion and have included additional LEfSE analyses for timepoints Pre and D4 of SFB+CRC+, SFB+CRC-, SFB-CRC+, and SFB-CRC- groups (4 classes per timepoint) as Fig S7 and added description of those figures within the text. The header “Family Enterobacteriaceae and SFB interact in CRC development” has been changed to “Family Enterobacteriaceae is predictive in SFB+ CRC development” to better reflect the observations within Fig 4B.

We agree completely. We clarified within the manuscript that the graphs in Figure 3C are the Bray-Curtis measurements generated from the line lengths in the PCoA of Figure 3B, and supported those claims with statistical tests.

We have clarified that each value given represents the Bray-Curtis Dissimilarity Index value between Pre and D4 of each individual mouse rather than the mean value at the Pre and D4 time-points (thus accounting for inter-individual variability), and that these are then categorized by SFB status and analyzed.

The reasons that Helicobacter spp. and Family Enterobactericeae were chosen were because of stark observations seen within the barchart in Fig 3A. It makes sense to look at Helicobacter spp. as the provocateur of inflammation within the disease model, and Family Enterobactericeae as a driver and passenger to inflammation. Testing for these has been done with a Yes/No basis for CRC, as Spearman rank correlations rarely yield an R value stronger than ±0.3 when relative abundance is compared to disease score. However, we have included a chart of OTU and Family level Spearman Rank Correlations for SFB+ and SFB- groups on Pre, D4, and D7 PI as Table 1 and included verbiage within the manuscript. That being said, we believe that these data should be interpreted cautiously, as multiple testing of this magnitude can lead to an exceedingly high false discovery rate, especially with many of the r values as low as they are.

6. "Colonies were identified using matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF)

mass spectrometry. Seven of the eight samples were identified as Escherichia coli, as expected (Figure

5A)" Because Figure 5A too much simplified the result of MALDI-TOF, the authors should attach the supplemental tables of identified bacterial molecules and describe which database was used for identification of the molecules. Moreover, the authors should describe justification for the reason why they used mass spec as genome sequencing of isolates gives more accurate and detailed results with low cost.

More information regarding MALDI-ToF was added to the materials and methods section regarding databases used. The information provided from a given isolate allow for taxonomic identification from a database based on the full surface protein spectrum, while no information is provided regarding the identity of specific protein markers.

MALDI-ToF was chosen as an initial identification modality due to the substantially lower costs associated with screening multiple isolates at our institution. For a pair of promising isolates, we did perform whole genome sequencing to search for specific genes which may contribute to disease, as stated in the manuscript.

As E. coli is easily culturable, in contrast to the many OTUs which cannot yet be cultured, this is a valid concern. Part of the rationale for these cultures was to better identify the members of family Enterobacteriaceae (particularly those falling under the Escherichia-Shigella sp. taxa) which might be proliferating, as there are many differences in strains that cannot be detected by 16S alone. We do not assume that we cultured every single individual strain of family Enterobacteriaceae, but are definitely intrigued by what we did isolate and intend on following up on these physical properties as well as the full-genome sequencing data from these two isolates. This will give us a better idea of E. coli-specific virulence factors found within the GIT of our Smad3-/- model as a starting point for mechanistic studies in the future.

8. What does the finding on hemolytic features of one E. coli strain (Fig, 5b) mean? Is this associated with the conclusions of this manuscript?

The alpha-hemolytic properties of E. coli are most commonly associated with invasive strains of E.coli rather than facultative ones. These strains have been found to play a role in intraperitoneal infections, which will be interesting to study in a mechanistic sense within our model. We have added verbiage concerning the implications of this finding in the Discussion.

Minor comments:

We apologize for the omission and have fixed this discrepancy in the text. The figures were correct, and the discrepant numbers reflect the data prior to discarding the SFB-exposed group (members of the SFB+ group which did not test positive for SFB at any timepoint via PCR as outlined in the materials/methods.) We have double-checked the stats/figures to make sure that these numbers reflect the final and correct ratios.

We have fixed these mistakes as well and clarified that weaning is at Day 21 within the figure.

11. The p values and the permutation number of PERMANOVA were missing in the text and/or Figures S2 and S3.

We have added the p values in the figure legends of Fig S2 and pairwise charts in Fig S3.

We appreciate the astute suggestion and have amended the mentioned graphs to box and whisker charts as requested.

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(22.9KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0236595.r003

Decision Letter 1

Hiroyasu Nakano

10 Jul 2020

Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development.

PONE-D-20-08853R1

Dear Dr. Ericsson

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Hiroyasu Nakano, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Reviewer #1: The authors addressed the reviewer’s concerns. Although the study is superficial, the results will contribute to the progress of the research field.

Reviewer #2: The authors have addressed all my comments well and the revised manuscript is suitable to publish in PLOS ONE.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

PLoS One. doi: 10.1371/journal.pone.0236595.r004

Acceptance letter

Hiroyasu Nakano

15 Jul 2020

PONE-D-20-08853R1

Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development.

Dear Dr. Ericsson:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Hiroyasu Nakano

Academic Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. SFB does not impact overall penetrance or severity of CAC.

Penetrance of CRC a), Tumor Scores b), and Overall Disease Scores c) in SFB- and SFB+ groups. Chi Square a) and Kruskal-Wallis One Way ANOVA on Ranks (b and c) performed.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S2 Fig. No early GM profile found to be predictive of CRC development.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S3 Fig. Examining the effects of cage and sex on CRC.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S4 Fig. Accompanying figure legend to Fig 3A.

Corresponding OTUs to each segment of the barcharts shown on Fig 3A.

(TIF)

Click here for additional data file.^{(4.8MB, tif)}

S5 Fig. Bray-Curtis dissimilarity Index examining total GM shifts between female and male mice within the SFB- and SFB+ groups from Pre-inoculation to D4 PI.

Two-Way Anova (post hoc Holm-Sidak) test performed. Only the overall differences between SFB+ and SFB- was significant (p = 0.015).

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S6 Fig. Helicobacter spp. and Family Enterobacteriaceae kinetics between male and female mice.

Relative abundance of a) Helicobacter spp. and b) Family Enterobacteriaceae in male and female SFB- and SFB+ mice which did and did not develop CRC. No stats were performed due to a low n.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

S7 Fig. LEfSe analysis at early timepoints.

Linear discriminant analysis effect size (LEfSe) on a) Pre-inoculation and b) D4 post-inoculation in SFB+CRC-, SFB+CRC+, SFB-CRC+, and SFB-CRC- groups.

(TIF)

Click here for additional data file.^{(2.4MB, tif)}

Attachment

Submitted filename: Response to Reviewers.docx

Click here for additional data file.^{(22.9KB, docx)}

Data Availability Statement

Data may be found in the SRA database under bioproject ID PRJNA548523. The reviewer link is as follows: https://dataview.ncbi.nlm.nih.gov/object/PRJNA548523?reviewer=9f68h3l705qbmaurmmg3r0b8hu.

[pone.0236595.ref001] 1.Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67(3):177–93. 10.3322/caac.21395 [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref002] 2.Ericsson AC, Myles M, Davis W, Ma L, Lewis M, Maggio-Price L, et al. Noninvasive detection of inflammation-associated colon cancer in a mouse model. Neoplasia. 2010;12(12):1054–65. 10.1593/neo.10940 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref003] 3.Lakatos P-L, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World journal of gastroenterology. 2008;14(25):3937–47. Epub 07/07. 10.3748/wjg.14.3937 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref004] 4.Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–14 e5. 10.1053/j.gastro.2010.01.058 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref005] 5.Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:1–5. 10.1046/j.1365-2036.18.s2.2.x . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref006] 6.Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: A nationwide Japanese study. Inflammatory Bowel Diseases. 2011;17(3):802–8. 10.1002/ibd.21365 [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref007] 7.de Vos WM, de Vos EAJ. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutrition Reviews. 2012;70(suppl_1):S45–S56. 10.1111/j.1753-4887.2012.00505.x [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref008] 8.Hart ML, Ericsson AC, Franklin CL. Differing Complex Microbiota Alter Disease Severity of the IL-10−/− Mouse Model of Inflammatory Bowel Disease. Frontiers in Microbiology. 2017;8(792). 10.3389/fmicb.2017.00792 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref009] 9.Fichtner-Feigl S, Kesselring R, Strober W. Chronic inflammation and the development of malignancy in the GI tract. Trends in immunology. 2015;36(8):451–9. Epub 07/18. 10.1016/j.it.2015.06.007 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref010] 10.Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt-Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer research. 2006;66(2):828–38. 10.1158/0008-5472.CAN-05-2448 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref011] 11.Fox JG. Helicobacter bilis: bacterial provocateur orchestrates host immune responses to commensal flora in a model of inflammatory bowel disease. Gut. 2007;56(7):898–900. 10.1136/gut.2006.115428 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref012] 12.Jergens AE, Wilson-Welder JH, Dorn A, Henderson A, Liu Z, Evans RB, et al. Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut. 2007;56(7):934–40. Epub 12/01. 10.1136/gut.2006.099242 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref013] 13.Ericsson AC, Davis JW, Spollen W, Bivens N, Givan S, Hagan CE, et al. Effects of vendor and genetic background on the composition of the fecal microbiota of inbred mice. PloS one. 2015;10(2):e0116704–e. 10.1371/journal.pone.0116704 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref014] 14.Ericsson AC, Akter S, Hanson MM, Busi SB, Parker TW, Schehr RJ, et al. Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. Oncotarget. 2015;6(32):33689–704. 10.18632/oncotarget.5604 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref015] 15.Klaasen HL, Van der Heijden PJ, Stok W, Poelma FG, Koopman JP, Van den Brink ME, et al. Apathogenic, intestinal, segmented, filamentous bacteria stimulate the mucosal immune system of mice. Infection and immunity. 1993;61(1):303–6. . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref016] 16.Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485–98. 10.1016/j.cell.2009.09.033 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref017] 17.Ivanov II, Frutos RdL, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell host & microbe. 2008;4(4):337–49. 10.1016/j.chom.2008.09.009 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref018] 18.Denning TL, Norris BA, Medina-Contreras O, Manicassamy S, Geem D, Madan R, et al. Functional specializations of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization. J Immunol. 2011;187(2):733–47. 10.4049/jimmunol.1002701 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref019] 19.Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–27. Epub 2010/07/14. 10.1016/j.immuni.2010.06.001 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref020] 20.Kriegel MA, Sefik E, Hill JA, Wu H-J, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proceedings of the National Academy of Sciences. 2011;108(28):11548–53. 10.1073/pnas.1108924108 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref021] 21.Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4615–22. 10.1073/pnas.1000082107 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref022] 22.Caselli M, Tosini D, Gafa R, Gasbarrini A, Lanza G. Segmented filamentous bacteria-like organisms in histological slides of ileo-cecal valves in patients with ulcerative colitis. Am J Gastroenterol. 2013;108(5):860–1. Epub 2013/05/07. 10.1038/ajg.2013.61 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref023] 23.Chen B, Chen H, Shu X, Yin Y, Li J, Qin J, et al. Presence of Segmented Filamentous Bacteria in Human Children and Its Potential Role in the Modulation of Human Gut Immunity. Front Microbiol. 2018;9:1403 10.3389/fmicb.2018.01403 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref024] 24.Ericsson AC, Turner G, Montoya L, Wolfe A, Meeker S, Hsu C, et al. Isolation of segmented filamentous bacteria from complex gut microbiota. Biotechniques. 2015;59(2):94–8. Epub 2014/01/01. 10.2144/000114319 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref025] 25.Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr. 1999;69(5):1046S–51S. Epub 1999/05/08. 10.1093/ajcn/69.5.1046s . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref026] 26.Ericsson AC, Hagan CE, Davis DJ, Franklin CL. Segmented filamentous bacteria: commensal microbes with potential effects on research. Comp Med. 2014;64(2):90–8. Epub 2014/03/29. [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref027] 27.Snel J, Hermsen CC, Smits HJ, Bos NA, Eling WM, Cebra JJ, et al. Interactions between gut-associated lymphoid tissue and colonization levels of indigenous, segmented, filamentous bacteria in the small intestine of mice. Can J Microbiol. 1998;44(12):1177–82. Epub 1999/05/29. 10.1139/cjm-44-12-1177 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref028] 28.Hammer ØH, David A. T.; Ryan, Paul D. PAST: Paleontological statistics software package for education and data analysis. Palaeontologia Electronica. 2001;4(1):9. [Google Scholar]

[pone.0236595.ref029] 29.Nougayrede JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313(5788):848–51. Epub 2006/08/12. 10.1126/science.1127059 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref030] 30.Ording AG, Horváth-Puhó E, Erichsen R, Long MD, Baron JA, Lash TL, et al. Five-Year Mortality in Colorectal Cancer Patients with Ulcerative Colitis or Crohn's DiseaseA Nationwide Population-based Cohort Study. Inflammatory Bowel Diseases. 2013;19(4):800–5. 10.1097/MIB.0b013e3182802af7 [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref031] 31.Roncucci L, Mariani F. Prevention of colorectal cancer: How many tools do we have in our basket? Eur J Intern Med. 2015;26(10):752–6. 10.1016/j.ejim.2015.08.019 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref032] 32.Yang Y, Torchinsky MB, Gobert M, Xiong H, Xu M, Linehan JL, et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature. 2014;510(7503):152–6. 10.1038/nature13279 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref033] 33.Jin S, Zhao D, Cai C, Song D, Shen J, Xu A, et al. Low-dose penicillin exposure in early life decreases Th17 and the susceptibility to DSS colitis in mice through gut microbiota modification. Sci Rep. 2017;7:43662 10.1038/srep43662 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref034] 34.Finotti A, Gasparello J, Lampronti I, Cosenza LC, Maconi G, Matarese V, et al. PCR detection of segmented filamentous bacteria in the terminal ileum of patients with ulcerative colitis. BMJ Open Gastroenterol. 2017;4(1):e000172 10.1136/bmjgast-2017-000172 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref035] 35.Yoshida N, Kinugasa T, Miyoshi H, Sato K, Yuge K, Ohchi T, et al. A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells). Annals of Surgical Oncology. 2016;23(3):919–27. 10.1245/s10434-015-4923-3 [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref036] 36.Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Medicine. 2008;14:282 10.1038/nm1720 https://www.nature.com/articles/nm1720#supplementary-information. [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref037] 37.Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut microbes. 2014;5(5):675–80. 10.4161/19490976.2014.969989 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref038] 38.Skals M, Jorgensen NR, Leipziger J, Praetorius HA. Alpha-hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis. Proc Natl Acad Sci U S A. 2009;106(10):4030–5. Epub 2009/02/20. 10.1073/pnas.0807044106 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref039] 39.Cavalieri SJ, Bohach GA, Snyder IS. Escherichia coli alpha-hemolysin: characteristics and probable role in pathogenicity. Microbiol Rev. 1984;48(4):326–43. Epub 1984/12/01. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref040] 40.May AK, Gleason TG, Sawyer RG, Pruett TL. Contribution of Escherichia coli alpha-hemolysin to bacterial virulence and to intraperitoneal alterations in peritonitis. Infect Immun. 2000;68(1):176–83. Epub 1999/12/22. 10.1128/iai.68.1.176-183.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref041] 41.Ghoreschi K, Laurence A, Yang X-P, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature. 2010;467:967 10.1038/nature09447 https://www.nature.com/articles/nature09447#supplementary-information. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref042] 42.Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, et al. Induction and molecular signature of pathogenic TH17 cells. Nature immunology. 2012;13(10):991–9. Epub 09/09. 10.1038/ni.2416 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref043] 43.Jewel Samadder N, Valentine JF, Guthery S, Singh H, Bernstein CN, Wan Y, et al. Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Digestive Diseases and Sciences. 2017;62(8):2126–32. 10.1007/s10620-016-4435-4 [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref044] 44.Lee SM, Kim N, Son HJ, Park JH, Nam RH, Ham MH, et al. The Effect of Sex on the Azoxymethane/Dextran Sulfate Sodium-treated Mice Model of Colon Cancer. J Cancer Prev. 2016;21(4):271–8. 10.15430/JCP.2016.21.4.271 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref045] 45.Moulton VR. Sex Hormones in Acquired Immunity and Autoimmune Disease. Front Immunol. 2018;9:2279 10.3389/fimmu.2018.02279 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref046] 46.Traish A, Bolanos J, Nair S, Saad F, Morgentaler A. Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. J Clin Med. 2018;7(12). 10.3390/jcm7120549 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref047] 47.Markle JG, Frank DN, Adeli K, von Bergen M, Danska JS. Microbiome manipulation modifies sex-specific risk for autoimmunity. Gut Microbes. 2014;5(4):485–93. 10.4161/gmic.29795 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref048] 48.Makino S, Kunimoto K, Muraoka Y, Katagiri K. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu. 1981;30(2):137–40. 10.1538/expanim1978.30.2_137 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref049] 49.Fox HS. Androgen treatment prevents diabetes in nonobese diabetic mice. J Exp Med. 1992;175(5):1409–12. 10.1084/jem.175.5.1409 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref050] 50.Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity. 2013;39(2):400–12. Epub 2013/08/27. 10.1016/j.immuni.2013.08.013 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref051] 51.Urdaci MC, Regnault B, Grimont PA. Identification by in situ hybridization of segmented filamentous bacteria in the intestine of diarrheic rainbow trout (Oncorhynchus mykiss). Res Microbiol. 2001;152(1):67–73. Epub 2001/04/03. 10.1016/s0923-2508(00)01169-4 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref052] 52.Snel J, Heinen PP, Blok HJ, Carman RJ, Duncan AJ, Allen PC, et al. Comparison of 16S rRNA sequences of segmented filamentous bacteria isolated from mice, rats, and chickens and proposal of "Candidatus Arthromitus". Int J Syst Bacteriol. 1995;45(4):780–2. 10.1099/00207713-45-4-780 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref053] 53.Yu Z, Morrison M. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques. 2004;36(5):808–12. 10.2144/04365ST04 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref054] 54.Hart ML, Ericsson AC, Lloyd KCK, Grimsrud KN, Rogala AR, Godfrey VL, et al. Development of outbred CD1 mouse colonies with distinct standardized gut microbiota profiles for use in complex microbiota targeted studies. Sci Rep. 2018;8(1):10107 Epub 2018/07/06. 10.1038/s41598-018-28448-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref055] 55.Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci USA. 2011;108 Suppl 1:4516–22. 10.1073/pnas.1000080107 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref056] 56.Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957–63. 10.1093/bioinformatics/btr507 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref057] 57.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011. 2011;17(1):3 Epub 2011-08-02. 10.14806/ej.17.1.200 [DOI] [Google Scholar]

[pone.0236595.ref058] 58.Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26(19):2460–1. 10.1093/bioinformatics/btq461 . [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref059] 59.Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. Current protocols in bioinformatics. 2011;Chapter 10:Unit10.7-.7. 10.1002/0471250953.bi1007s36 . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref060] 60.Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nature Methods. 2013;10:996 10.1038/nmeth.2604 https://www.nature.com/articles/nmeth.2604#supplementary-information. [DOI] [PubMed] [Google Scholar]

[pone.0236595.ref061] 61.Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Research. 2012;41(D1):D590–D6. 10.1093/nar/gks1219 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref062] 62.Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60 Epub 2011/06/28. 10.1186/gb-2011-12-6-r60 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0236595.ref063] 63.Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. 2015. 2015;67(1):48 Epub 2015-10-07. 10.18637/jss.v067.i01 [DOI] [Google Scholar]

[pone.0236595.ref064] 64.Weisberg JFaS. An R Companion to Applied Regression. Third ed Thousand Oaks, CA: Sage Publications; 2019. [Google Scholar]

PERMALINK

Interactions of Segmented Filamentous Bacteria (Candidatus Savagella) and bacterial drivers in colitis-associated colorectal cancer development

Annie E Wolfe

Jacob E Moskowitz

Craig L Franklin

Timothy L Wiemken

Aaron C Ericsson

Roles

Abstract

Introduction

Results

Experimental design

Fig 1. Experimental design.

No SFB-dependent difference in penetrance or severity of CAC

No early GM profile found to be predictive of CRC development

Interactions between sex and SFB influence incidence and severity of CRC

Fig 2. Sex and SFB interactions influence incidence and severity of CRC.

SFB impacts the GM of Smad3-/- mice during disease development

Fig 3. SFB stabilizes the GM and prevents large shifts in GM structure following Helicobacter spp. inoculation.

SFB stabilizes the gut microbiota following Helicobacter spp.-inoculation

Presence of SFB alters which taxa correlate with disease severity

Table 1. Spearman’s ranked correlation of bacterial families at Pre, D4, and D7 in SFB+ and SFB- mice.

Table 2. Spearman’s ranked correlation of bacterial OTUs at Pre, D4, and D7 in SFB+ and SFB- mice.

Relative abundance of Helicobacter spp. at D4 PI predictive of CRC development in SFB- but not SFB+ mice

Fig 4. Relative abundance of Helicobacter spp. at D4 PI predictive of CRC development in SFB- but not SFB+ mice.

Family Enterobacteriaceae is predictive of CRC development in SFB+ mice only

Fig 5. Isolation of family Enterobacteriaceae.

Discussion

Materials and methods

Animals

SFB PCR confirmation

Bacterial culture

Helicobacter spp. inoculation

Fecal sample collection

Tissue sample collection

DNA extraction

16S rDNA library preparation and sequencing

Informatics analysis

Histopathology

Anaerobic bacterial culture and identification

E.coli Isolate genome sequencing

Statistical analysis

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Hiroyasu Nakano

Roles

Author response to Decision Letter 0

Decision Letter 1

Hiroyasu Nakano

Roles

Acceptance letter

Hiroyasu Nakano

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

SFB impacts the GM of Smad3^-/- mice during disease development